Study of sprinolactone effect as a treatment for Acute Central Serous Chorio-Retinopathy

BACKGROUND AND OBJECTIVE:
Central serous chorioretinopathy (CSCR) is a vision-threatening eye disease with no validated treatment and unknown pathogeny.The disease usually becomes better within 3-4 months but in some cases, recurrent or chronic, progressive loss of visual acuity is associated with. No effective drug therapy has not been seen for treatment of CSCR.
Overaction of mineralocorticoid receptor (MR) pathways has been implicated in the pathophysiology of central serous chorioretinopathy (CSCR). The purpose of this study was to evaluate MR antagonists in the treatment of CSCR. the disease in young and middle ages can be seen so Reduce the duration of illness and increase the quality of life is considered in this study.
STUDY DESIGN AND METHODS:
The study randomized clinical trail (RCT) as a double-blind and 40 patients were admitted in 1394-1393 to Shahid Sadducees hospital were diagnosed with acute CSCR. In this study, patients treated with placebo control group and the group treated with spironolactone 25 mg daily, respectively. Demographic (age, gender, etc.) and visual acuity (bcva, logmar) and cmt at certain times pre-treatment, two weeks after treatment and one month after treatment were measured with the Snellen chart and OCT.
RESULTS:
After a month of treatment success in the group treated with spironolactone was 72.2% and 35.3% in the control group was shown. (0.028 p value)
Visual acuity in the group treated with spironolactone became better and changes of visual acuity logmar 0.463 to 0.108 was observed after one month of therapy.In the treatment group Cmt before treatment was 550 µm after treatment (with significant reduction of 43.43% 239 µm) became 311 µm in one month after use spironolactone. There was no complication in the treatment.
CONCLUSIONS:
The study showed that the use of spironolactone 25 mg tablets in the acute phase (the first month) improvement in visual acuity and cmt in cscr disease, and the results of this study reinforce the Mineralocorticoid in the pathogenesis of the disease. Further analysis is required in the following reference.